BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 9767460)

  • 1. T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A.
    Sundstedt A; Grundström S; Dohlsten M
    Immunology; 1998 Sep; 95(1):76-82. PubMed ID: 9767460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
    Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
    Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
    Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo.
    Rosendahl A; Hansson J; Antonsson P; Sékaly RP; Kalland T; Dohlsten M
    Infect Immun; 1997 Dec; 65(12):5118-24. PubMed ID: 9393804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant Disruption of
    Chowdhary VR; Krogman A; Tilahun AY; Alexander MP; David CS; Rajagopalan G
    J Immunol; 2017 Jun; 198(11):4413-4424. PubMed ID: 28468970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superantigen-induced lysis of melanoma cells.
    Krull F; Holzer U; Ihle J; Bethge W; Fierlbeck G; Kalland T; Dohlsten M; Niethammer D; Dannecker GE
    Melanoma Res; 1997 Jun; 7(3):214-22. PubMed ID: 9195560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class II.
    Stohl W; Xu D; Zang S; Kim KS; Li L; Hanson JA; Stohlman SA; David CS; Jacob CO
    Int Immunol; 2001 Oct; 13(10):1291-300. PubMed ID: 11581174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
    J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homeostatic regulation of CD8+ T cells by perforin.
    Kägi D; Odermatt B; Mak TW
    Eur J Immunol; 1999 Oct; 29(10):3262-72. PubMed ID: 10540338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
    Lamphear JG; Stevens KR; Rich RR
    J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
    Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
    Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
    Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial superantigens reactivate antigen-specific CD8+ memory T cells.
    Coppola MA; Blackman MA
    Int Immunol; 1997 Sep; 9(9):1393-403. PubMed ID: 9310843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of T cells by superantigen in class II-negative mice.
    Avery AC; Markowitz JS; Grusby MJ; Glimcher LH; Cantor H
    J Immunol; 1994 Dec; 153(11):4853-61. PubMed ID: 7963549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo.
    Belfrage H; Dohlsten M; Hedlund G; Kalland T
    Cancer Immunol Immunother; 1995 Aug; 41(2):87-94. PubMed ID: 7656274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
    J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.